EMEA-001349-PIP01-12-M03 - paediatric investigation plan

daclizumab

Key facts

• Active substance:
  daclizumab
• Therapeutic area:
  Neurology
• Decision number:
  P/0005/2020
• PIP number:
  EMEA-001349-PIP01-12-M03
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of multiple sclerosis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  06/01/2020
• Compliance check done:
  No

Decision

P/0005/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for daclizumab (EMEA-001349-PIP01-12-M03)

Adopted Reference Number: EMA/672291/2019